These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


386 related items for PubMed ID: 27807302

  • 1. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
    Motzer RJ, Escudier B, Gannon A, Figlin RA.
    Oncologist; 2017 Jan; 22(1):41-52. PubMed ID: 27807302
    [Abstract] [Full Text] [Related]

  • 2. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R.
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [Abstract] [Full Text] [Related]

  • 6. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.
    JAMA; 2006 Jun 07; 295(21):2516-24. PubMed ID: 16757724
    [Abstract] [Full Text] [Related]

  • 8. Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma.
    Lee CH, Motzer RJ.
    Urol Oncol; 2015 Jun 07; 33(6):275-9. PubMed ID: 25465298
    [Abstract] [Full Text] [Related]

  • 9. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R.
    Clin Cancer Res; 2007 Mar 01; 13(5):1367-73. PubMed ID: 17332278
    [Abstract] [Full Text] [Related]

  • 10. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
    Patel KB, Panchal HP, Karanwal AB, Parekh BB, Shah S, Prasad S.
    Indian J Cancer; 2016 Mar 01; 53(1):118-22. PubMed ID: 27146758
    [Abstract] [Full Text] [Related]

  • 11. Sunitinib in solid tumors.
    Gan HK, Seruga B, Knox JJ.
    Expert Opin Investig Drugs; 2009 Jun 01; 18(6):821-34. PubMed ID: 19453268
    [Abstract] [Full Text] [Related]

  • 12. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.
    Adv Ther; 2017 Nov 01; 34(11):2452-2465. PubMed ID: 29076108
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
    Kuczyk M, Kruck S, Merseburger AS.
    Urologe A; 2007 May 01; 46(5):504-8, 510. PubMed ID: 17437075
    [Abstract] [Full Text] [Related]

  • 14. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
    Khosravan R, Motzer RJ, Fumagalli E, Rini BI.
    Clin Pharmacokinet; 2016 Oct 01; 55(10):1251-1269. PubMed ID: 27154065
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W, Shen Z.
    Urol Oncol; 2013 Nov 01; 31(8):1800-5. PubMed ID: 22658883
    [Abstract] [Full Text] [Related]

  • 16. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
    Theou-Anton N, Faivre S, Dreyer C, Raymond E.
    Drug Saf; 2009 Nov 01; 32(9):717-34. PubMed ID: 19670913
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA, Goldspiel BR.
    Pharmacotherapy; 2007 Aug 01; 27(8):1125-44. PubMed ID: 17655513
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
    Abdel-Rahman O, Fouad M.
    Crit Rev Oncol Hematol; 2015 May 01; 94(2):238-50. PubMed ID: 25638704
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS, Wu X, Zhao PJ, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, Wang G, He ZS, Zhou LQ, Jin J.
    Chin Med J (Engl); 2011 Sep 01; 124(18):2920-4. PubMed ID: 22040503
    [Abstract] [Full Text] [Related]

  • 20. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 20.